Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 11:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 10,525 matching trials from the live ClinicalTrials.gov search.
Filters: Active, not recruiting Clear all
Active, not recruiting Not applicable Interventional

INHANCE Stemless Reverse Shoulder IDE

NCT06323980
View directory record Official record
Conditions
Arthroplasty, Replacement, Shoulder
Interventions
Reverse Total Shoulder
Device
Lead sponsor
DePuy Orthopaedics
Industry
Eligibility
22 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
15
States / cities
Atlantis, Florida • Waltham, Massachusetts • Grand Rapids, Michigan + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 9, 2026, 11:03 AM EST
Active, not recruiting Phase 2 Interventional

A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)

NCT06282159
View directory record Official record
Conditions
Myasthenia Gravis, Generalized
Interventions
Claseprubart, Placebo
Drug
Lead sponsor
Dianthus Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
21
States / cities
Phoenix, Arizona • Irvine, California • Stamford, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Nov 9, 2026, 11:03 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Olive Oil Polyphenols and Cardiovascular Health Biomarkers

NCT04149288
View directory record Official record
Conditions
Healthy, Normal Weight, Overweight, Obese
Interventions
High-polyphenol olive oil, Low-polyphenol olive oil
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
20 Years to 45 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Nov 9, 2026, 11:03 AM EST
Active, not recruiting Not applicable Interventional

An Early Feasibility Study Evaluation of an Implant Free Interatrial Shunt to Improve Heart Failure

NCT06859970
View directory record Official record
Conditions
Heart Failure, Heart Failure NYHA Class III, Heart Failure With Reduced Ejection Fraction, Ambulatory Heart Failure, NYHA Class IV
Interventions
PAS-C System
Device
Lead sponsor
InterShunt Technologies, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
6
States / cities
Jonesboro, Arkansas • Thousand Oaks, California • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Nov 9, 2026, 11:03 AM EST
Active, not recruiting Not applicable Interventional

Fitness and Nutrition in Glioma

NCT06665373
View directory record Official record
Conditions
Malignant Glioma
Interventions
Modified Atkins Diet, Fitness Program
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Nov 9, 2026, 11:03 AM EST
Active, not recruiting Phase 1 Interventional

A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

NCT06318273
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
ABBV-969
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Male only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Duarte, California • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Nov 9, 2026, 11:03 AM EST
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions

NCT05432583
View directory record Official record
Conditions
Genital Herpes Simplex Type 2
Interventions
BNT163, Placebo
Biological · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 55 Years
Enrollment
318 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
6
States / cities
Tempe, Arizona • Chicago, Illinois • Raleigh, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 9, 2026, 11:03 AM EST
Active, not recruiting Phase 3 Interventional

Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer

NCT03949283
View directory record Official record
Conditions
Recurrent Ovarian Carcinoma, Platinum-resistant Ovarian Cancer
Interventions
ChemoID Assay, Standard Chemotherapy
Diagnostic Test · Drug
Lead sponsor
Cordgenics, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
8
States / cities
Los Angeles, California • Miami, Florida • New Orleans, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Nov 9, 2026, 11:03 AM EST
Active, not recruiting Not applicable Interventional

Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency

NCT01787409
View directory record Official record
Conditions
Aggressive Non-Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Hepatosplenic T-Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma, Nasal Type Extranodal NK/T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Primary Cutaneous Anaplastic Large Cell Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Small Lymphocytic Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma
Interventions
Cholecalciferol, Laboratory Biomarker Analysis
Dietary Supplement · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
5
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Nov 9, 2026, 11:03 AM EST
Active, not recruiting Phase 2 Interventional

TArgeting Type 1 Diabetes Using POLyamines (TADPOL)

NCT05594563
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
DFMO, Placebo
Drug
Lead sponsor
Emily K. Sims
Other
Eligibility
4 Years to 40 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Aurora, Colorado • Chicago, Illinois • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Nov 9, 2026, 11:03 AM EST
Active, not recruiting Phase 4 Interventional

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

NCT03535298
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Early Highly Effective Therapies Group, Escalation Therapies Group
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
15
States / cities
Aurora, Colorado • Minneapolis, Minnesota • Rochester, Minnesota + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Nov 9, 2026, 11:03 AM EST
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Hormonal Mechanisms of Sleep Restriction - Axis Study

NCT03142893
View directory record Official record
Conditions
Sleep Restriction
Interventions
Ketoconazole Pill, Ganirelix, Dexamethasone, Dexamethasone Injection, Cosyntropin Injectable Product, Recombinant Human Luteinizing Hormone, Hydrocortisone Injection, Gonadorelin, Corticorelin, Placebo oral capsule, Saline Solution, Saline Solution for Injection
Drug
Lead sponsor
Peter y. Liu
Other
Eligibility
22 Years to 45 Years · Male only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Nov 9, 2026, 11:03 AM EST
Active, not recruiting Phase 2 Interventional Results available

Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)

NCT06390852
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Larotrectinib, Magnetic Resonance Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 9, 2026, 11:03 AM EST
Active, not recruiting Not applicable Interventional

Treatment of PAF With the Synaptic System

NCT05905835
View directory record Official record
Conditions
Paroxysmal Atrial Fibrillation
Interventions
Synaptic Cryoablation System
Device
Lead sponsor
Synaptic Medical Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Nov 9, 2026, 11:03 AM EST
Active, not recruiting Phase 1 Interventional

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

NCT03821935
View directory record Official record
Conditions
Advanced Solid Tumors Cancer
Interventions
Livmoniplimab, Budigalimab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
21
States / cities
Springdale, Arkansas • Duarte, California • Irvine, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Nov 9, 2026, 11:03 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

The MURDOCK Study Registry and Biorepository Horizon 1.5

NCT01708408
View directory record Official record
Conditions
Chronic Disease, Healthy Volunteers
Interventions
Biomarker studies
Genetic
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
50,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2026
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Nov 9, 2026, 11:03 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Mapping the Shift Worker's Microbiome

NCT03221517
View directory record Official record
Conditions
Healthy
Interventions
Standardized meal with a glucose challenge test
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 59 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Nov 9, 2026, 11:03 AM EST
Active, not recruiting Not applicable Interventional

Efficacy & Safety of LOBO™ Vascular Occlusion Device for Embolization of Pulmonary Arteriovenous Malformations

NCT06735976
View directory record Official record
Conditions
Pulmonary Arteriovenous Malformations
Interventions
PAVM Embolization, PAVM Embolization with a LOBO™ device
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
14 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 6, 2026 · Synced Nov 9, 2026, 11:03 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

LEADing Dementia End-of-Life Planning Conversations

NCT05909189
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
LEADing Dementia End-of-Life Planning Conversations
Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Nov 9, 2026, 11:03 AM EST
Active, not recruiting Phase 1 Interventional

Stool Transplant to Control Treatment-related Diarrhea

NCT04883762
View directory record Official record
Conditions
Fecal Microbiota Transplantation (FMT)
Interventions
Fecal Microbiota Transplantation (FMT)
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Nov 9, 2026, 11:03 AM EST
Active, not recruiting Phase 1 Interventional

Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

NCT06342986
View directory record Official record
Conditions
Gynecologic Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer
Interventions
FT536, Fludarabine, CY
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Nov 9, 2026, 11:03 AM EST
Active, not recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)

NCT06534983
View directory record Official record
Conditions
Muscle-invasive Urothelial Carcinoma
Interventions
Autogene Cevumeran, Nivolumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 9, 2026, 11:03 AM EST
Active, not recruiting Not applicable Interventional

Trauma-Informed Procedural Pain Intervention: Refinement of an Evidence-Based Protocol

NCT06705491
View directory record Official record
Conditions
Procedural Pain, Cancer-related Pain
Interventions
TIPPI-R
Behavioral
Lead sponsor
University of Louisville
Other
Eligibility
Up to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Lexington, Kentucky • Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Nov 9, 2026, 11:03 AM EST
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

A Single Center, Open-Label Study to Evaluate the Ability of the TearScience™ LipiView™ II Ocular Surface Interferometer and the Keratograph® 5M to Detect Tear Film Stability Utilizing Miebo®

NCT07722624
View directory record Official record
Conditions
Dry Eye
Interventions
Determine the ability of the TearScience™ LipiView™ II Ocular Surface Interferometer and the Keratograph® 5M to detect tear film stability utilizing Miebo®
Drug
Lead sponsor
The Eye Care Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Nov 9, 2026, 11:03 AM EST